Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation

Leukemia

Volumn 18, Issue 6, 2004, Pages 1127-1137

  Kubota, Y ^a   Tanaka, T ^b   Ohnishi, H ^a   Kitanaka, A ^a   Okutani, Y ^a   Taminato, T ^a   Ishida, T ^a   Kamano, H ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Bcr Abl; CML; Myeloproliferative disorders; Pl3 kinase; Platelet aggregation; Thrombopoietin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ABELSON KINASE; ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BCR ABL PROTEIN; CD63 ANTIGEN; CYTOTOXIC AGENT; HYDROXYUREA; IMATINIB; JANUS KINASE; JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; THROMBOPOIETIN; WORTMANNIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANDROSTANE DERIVATIVE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; TYROSINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTHEMIA; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IN VITRO STUDY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; BLOOD PLATELETS; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MORPHOLINES; PHOSPHORYLATION; PLATELET AGGREGATION; THROMBOPOIETIN; TYROSINE;

EID: 2942677280     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403370     Document Type: Article

References (48)

1. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA et al. Stimulation of megakaryocytopoieis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-538.
2. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-568.
3. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M et al. c-Mpl ligand is a humoral regulator of megakaryopoiesis. Nature 1994; 369: 571-574.
4. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77: 1117-1124.
5. Sohma Y, Akahori H, Seki N, Hori T, Ogami K, Kato T et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1995; 353: 57-61.
6. Mathia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82: 1395-1401.
7. Kojima H, Hamazaki Y, Nagata Y, Todokoro K, Nagasawa T, Abe T. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost 1995; 74: 1541-1545.
8. Kubota Y, Arai T, Tanaka T, Yamaoka C, Kiuchi H, Kajikawa T et al. Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation. Stem Cells 1996; 14: 439-444.
9. Montrucchio C, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi C. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87: 2762-2768.
10. Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996; 87: 4664-4670.
11. Hofmann WK, Ottmann OG, Hoelzer D. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies? Leukemia 1999; 13: 14-18.
12. Kaushansky K. Use of thrombopoietic growth factors in acute leukemia. Leukemia 2000; 14: 505-508.
13. Kuter DJ, Begley CC. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100: 3457-3469.
14. Wehmeier A, Sudhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 1997; 23: 391-402.
15. Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H et al. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood 1996; 88: 4304-4313.
16. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998; 338: 572-580.
17. Le Blanc K, Andersson P, Samuelsson J. Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera. Br J Haematol 2000; 108: 80-85.
18. Tefferi A, Yoon SY, Li CY. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood 2000; 96: 771-772.
19. Horikawa Y, Matsumura I, Hashimoto K, Shiraga M, Kosugi S, Tadokoro S et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90: 4031-4038.
20. Kiladjian JJ, Elkassar N, Hetet G, Briere J, Grandchamp B, Gardin C. Study of the thrombopoietin receptor in essential thrombocythemia. Leukemia 1997; 11: 1821-1826.
21. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, a c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995; 374: 48-52.
22. Miyakawa Y, Oda A, Druker BJ, Kato T, Miyazaki H, Handa M et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood 1995; 86: 23-27.
23. Rodriguez-Linares B, Watson SP. Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation. Biochem J 1996; 316: 93-98.
24. Usuki K, Iki S, Endo M, Izutsu K, Inoue K, Nishimura T et al. Influence of thrombopoietin on platelet activation in myeloproliferative disorders. Br J Haematol 1997; 97: 530-537.
25. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590-603.
26. Lee Jr JT, McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002; 16: 486-507.
27. Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K et al. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 2003; 17: 1-8.
28. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 2000; 1470: M21-M35.
29. Rittenhouse SE. Phosphoinositide 3-kinase activation and platelet function. Blood 1996; 88: 4401-4414.
30. Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86: 4054-4062.
31. Pasquet JM, Gross BS, Gratacap MP, Quek L, Pasquet S, Payrastre B et al. Thrombopoietin potentiates collagen receptor signaling in platelets through a phosphatidylinositol 3-kinase-dependent pathway. Blood 2000; 95: 3429-3434.
32. Zauli G, Bassini A, Vitale M, Gibellini D, Celeghini C, Caramelli E et al. Thrombopoietin enhances the alpha IIb beta 3-dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase. Blood 1997; 89: 883-895.
33. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996; 379: 645-648.
34. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
35. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-1942.
36. La Rosee P, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Clivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 2002; 16: 1213-1219.
37. Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994; 218: 284-294.
38. Kubota Y, Tanaka T, Kitanaka A, Ohnishi H, Okutani Y, Waki M et al. Src transduces erythropoietin-incluced differentiation signals through phosphatidylinositol 3-kinase. EMBO J 2001; 20: 5666-5677.
39. Kubota Y, Tanaka T, Yamaoka G, Yamaguchi M, Ohnishi H, Kawanishi K et al. Wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, inhibits erythropoietin-induced erythroid differentiation of K562 cells. Leukemia 1996; 10: 720-726.
40. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16: 6151-6161.
41. Best D, Pasquet S, Littlewood TJ, Brunskill SJ, Pallister CJ, Watson SP. Platelet activation via the collagen receptor GPVI is not altered in platelets from chronic myeloid leukaemia patients despite the presence of the constitutively phosphorylated adapter protein CrkL. Br J Haematol 2001; 112: 609-615.
42. ten Bosch GJ, Kessler JH, Blom J, Joosten AM, Gambacorti-Passerini C, Melief C, et al. BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. Br J Haematol 1998; 103: 1109-1115.
43. Vassbotn FS, Havnen OK, Heldin CH, Holmsen H. Negative feedback regulation of human platelets via autocrine activation of the platelet-derived growth factor alpha-receptor. J Biol Chem 1994; 269: 13874-13879.
44. Grabarek J, Groopman JE, Lyles YR, Jiang S, Bennett L, Zsebo K et al. Human kit ligand (stem cell factor) modulates platelet activation in vitro. J Biol Chem 1994; 269: 21718-21724.
45. Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia - potential clinical significance. Leukemia 2002; 16: 170-177.
46. Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K et al. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995; 91: 661-663.
47. Hallek M, Danhauser-Riedl S, Herbst R, Warmuth M, Winkler A, Kolb HJ et al. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol 1996; 94: 5-16.
48. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189-218.